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BACKGROUND: Circulating tumour cells (CTCs) offer a non-invasive approach to obtain and characterise metastatic tumour cells, but
their usefulness has been limited by low CTC yields from conventional isolation methods.
METHODS: To improve CTC yields and facilitate their molecular characterisation we compared the Food and Drug Administration-
approved CellSearch Epithelial Kit (CEK) to a simplified CTC capture method, CellSearch Profile Kit (CPK), on paired blood samples
from patients with metastatic breast (n¼75) and lung (n¼71) cancer. Molecular markers including Human Epidermal growth factor
Receptor 2 (HER2) were evaluated on CTCs by fluorescence in situ hybridisation (FISH) and compared to patients’ primary and
metastatic cancer.
RESULTS: The median cell count from patients with breast cancer using the CPK was 117 vs 4 for CEK (Po0.0001). Lung cancer
samples were similar; CPK: 145 cells vs CEK:4 cells (Po0.0001). Recovered CTCs were relatively pure (60–70%) and were evaluable
by FISH and immunofluorescence. A total of 10 of 30 (33%) breast cancer patients with HER2-negative primary and metastatic tissue
had HER2-amplified CTCs.
CONCLUSION: The CPK method provides a high yield of relatively pure CTCs, facilitating their molecular characterisation. Circulating
tumour cells obtained using CPK technology demonstrate that significant discordance exists between HER2 amplification of a
patient’s CTCs and that of the primary and metastatic tumour.
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The need for access to samples of metastatic cancer and the
inherent difficulty in obtaining these using conventional biopsies,
has led to interest in alternative sources of metastatic cells. One
such alternative is to analyse circulating tumour cells (CTCs).
Circulating tumour cells are thought to be quite rare in the blood
of most patients with metastatic disease – it has been estimated
that they are present at a frequency of 1 in 10
9 blood cells (Mostert
et al, 2009). Circulating tumour cells provide the potential ability
to monitor metastatic disease, prognostic information and a
means to perform non-invasive molecular interrogation of cancers,
as these cells can provide a molecular snapshot, or real-time
biopsy, of tumour cells. Circulating tumour cells can also
potentially be used to determine the mechanisms of acquired
resistance to targeted therapies, which only occur or evolve during
the course of drug treatment. The ability to isolate a relatively large
number of pure CTCs is necessary for these downstream
applications.
Circulating tumour cells have become increasingly accepted as
both an independent prognostic factor and as a marker of
therapeutic response and attempts have been made to standardise
their isolation and characterisation (Hayes and Smerage, 2008).
The automated CellSearch System (Veridex; Warren, NJ, USA) is
the first method to be clinically approved by the United States
Food and Drug Administration to capture and detect CTCs. This
system relies on immunomagnetic isolation followed by the use of
fluorescence microscopy for analysis. Two different but related
methods of sample preparation, the CellSearch Epithelial Cell Kit
(CEK) and the CellSearch Profile Kit (CPK) are currently available.
Both methods use a positive immunomagnetic selection with anti-
epithelial cell adhesion molecule antibodies linked to iron particles
to enrich for CTCs. In the CEK system, captured cells are
permeabilised and labelled with cytokeratin and CD45-specific
antibodies, and the nuclear stain 40-6-diamidino-2-phenylindole
(DAPI), and are analysed by semi-automated counting of
appropriately labelled CTCs (Riethdorf et al, 2007). In contrast,
the CPK procedure does not involve labelling or enumerating the
cells, but rather only uses the anti-epithelial cell adhesion molecule
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santibody coupled to iron particles to yield an enriched population
of CTCs, which can be used for molecular analyses. However, in
contrast to the CEK method, the CPK procedure is not Food and
Drug Administration approved for clinical management.
The primary limitation of the CEK system is the low yield of
CTCs. In several large clinical trials of patients with metastatic
breast cancer, the median number of isolated CTCs was five per
7.5ml of blood (Budd et al, 2006; Hayes et al, 2006; Hayes and
Smerage, 2008). Although the low numbers of CTCs are sufficient
to provide clinical prognostic information, in which a cutoff of X5
CTCs per 7.5ml of blood is used to delineate a poor prognosis
population, the ability to perform molecular analyses of the CTCs
is limited. In addition, it has been reported that the degree of
leukocyte contamination using the CEK system is quite high,
which further complicates molecular analyses of CTCs. These
limitations have led to the development of alternative CTC
isolation methods, including technologies based on size filtration,
density gradients, and microfluidic techniques, which have
demonstrated increased yields of CTCs (Vona et al, 2000; Nagrath
et al, 2007; Adams et al, 2008; Williams et al, 2009). For example, a
microfluidic chip-based CTC technology has been developed,
which isolates relatively high numbers of CTCs and can be used to
non-invasively detect drug-sensitive and -resistant epidermal
growth factor receptor (EGFR) mutations from non-small cell
lung cancer (NSCLC) patients (Nagrath et al, 2007; Maheswaran
et al, 2008). This method uses epithelial cell adhesion molecule-
specific antibodies that are conjugated to posts within the CTC
chip. Currently this system is limited by the lack of widespread
availability of the system, the inability to release the CTCs from the
microfluidic posts, prolonged processing time (samples are run at
1–2mlh
–1), and the requirement that samples be processed within
a few hours of collection (Nagrath et al, 2007).
To address some of the limitations of current CTC systems, we
evaluated the CPK system as a method to isolate and study CTCs.
Unexpectedly, this method resulted in isolation of 420-fold more
CTCs than the CEK method. We further characterised the purity of
the isolated CTCs and evaluated them using immunofluorescence
(IF) and fluorescence in situ hybridisation (FISH). Our findings
suggest that a modification in the use of the current CellSearch
system can result in a significant increase in the ability to isolate and
characterise CTCs from patients with breast cancer and NSCLC.
MATERIALS AND METHODS
Patients
Between December 2007 and March 2009 patients with metastatic
NSCLC (n¼71) or metastatic breast cancer (n¼75) were identified
from the Thoracic Oncology and Women’s Cancer clinics at the
Dana Farber Cancer Institute. Characteristics of the patients are
described in the Supplementary Table S1. The blood was collected
from each donor into CellSave blood collection tubes (Veridex) or
ethylenediaminetetraacetic acid (EDTA) tubes, where specified. The
blood samples were maintained at room temperature and processed
within a maximum of 72h after collection. All samples from patients
with breast cancer were obtained at the time they were initiating a
new therapy for the treatment of their disease. All of the samples
from patients with NSCLC were obtained while the patient was
currently under therapy. Control blood samples were drawn from
healthy volunteers with no history of malignant disease. All patients
provided written informed consent, and studies were approved by
the Dana Farber Cancer Institute Institutional Review Board (IRB).
Sample processing and counting
Samples were processed using the CEK method, including semi-
automated counting, according to the manufacture’s instructions
(Johnson & Johnson, 2008). Samples processed using the CPK
method (per manufacture’s instructions, (Johnson & Johnson,
2008)) were collected in a dilution buffer (phosphate buffered
saline, 0.5% bovine serum albumin and 0.1% sodium azide) and
immediately transferred to glass slides as cytospin preparations
using a ThermoFisher Cytospin 3. The centrifugation was
performed at 500g for 5min with a cytology funnel, thin filter
(Thermo Fisher Scientific, Pittsburgh, PA, USA), and a SuperFrost
Plus slide (Thermo Fischer Scientific). The cells on the resulting
cytospin slide were fixed with methanol for IF or immunohis-
tochemistry or fixed with methanol:acetic acid (3:1) for FISH.
Cells were stained with anti-cytokeratin phycoerythrin/DAPI/
CD45-allophycocyanin (Dako, Carpinteria, CA, USA) and then
manually counted using a standard fluorescence microscope
(Olympus, Center Valley, PA, USA). Cytokeratin staining was
considered positive when cells displayed unequivocal cytoplasmic
cytokeratin staining in a ring-like pattern (confirming an intact
cytoplasm) surrounding an intact nucleus.
Cell lines and reagents
The breast cancer cell line SK-BR-3 was obtained from American
Type Culture Collection. The EGFR-mutant (del E746_A750)
NSCLC cell line, HCC827, has been described previously
(Mukohara et al, 2005). The two cell lines were grown in
Dulbecco’s Modified Eagle Medium or Roswell Park Memorial
Institute 1640 (CellGrowth, Invitrogen, Life Technologies,
Carlsbad, CA, USA) respectively, supplemented with 10% foetal
bovine serum. Gefitinib and lapatinib were obtained from commercial
sources. Stock solutions of both drugs were prepared in dimethyl
sulphoxide and stored at  201C. For in vitro recovery experiments
SKBR3 cells were grown in DMEM with 10% foetal bovine serum,
10mgml
–1 EGF, and 1.5mML -glutamine. The HCC287 cells were
grown in ACL4 (Invitrogen, Life Technologies) with 10% foetal
bovine serum. For detailed methods see Supplementary methods.
Fluorescence in situ hybridisation (FISH)
The EGFR/CEP 7 and Human Epidermal growth factor Receptor 2
(HER2)/Centromere Probe 17 (CEP17) bacterial artificial chromo-
some (BAC) probes were obtained from Vysis Molecular (Abbot
Park, IL, USA). BAC mesenchymal-epithelial transition factor
(MET) (RP11-95I20) was obtained from CHORI (Children Oakland
Research Hospital, Oakland, CA, USA). Labelling was done with
the Nick Translation Kit (Vysis, Abbott Molecular, Des Plaines, IL,
USA). See Supplementary data for detailed methods of FISH
analysis of CTC, and for IF and immunohistochemistry staining
methods.
RESULTS
The CPK method isolates a greater number of cells than
the CEK method
We hypothesised that CTCs may be lost in the additional
permeabilisation, labelling, and wash steps specific to the CEK
method, particularly if CTCs are more ‘fragile’ than other cell
types. To directly compare the yield of cells isolated using CEK and
CPK procedures, we collected two peripheral blood samples from
patients with metastatic breast cancer (n¼75) and NSCLC
(n¼71), and processed them in parallel. Cells obtained using the
CPK method were counted manually and were compared with the
standard CEK counts obtained using the CellSearch system. The
median cell count from patients with breast cancer using the CPK
method was 116.5 per 7.5ml of blood (range 4–2432) compared
with 4 (range 0–57) using the CEK method (Po0.0001, Figure 1A).
The median cell count from patients with NSCLC processed using
the CPK method was 145 per 7.5ml of blood (range 5–1801)
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scompared with 4 (range 0–53) using the CEK procedure (Po0.0001;
Figure 1B). We also compared these findings on a per patient basis
(Supplementary Figures S1A and B) and demonstrated that for all
patients, the cell count by the CPK method exceeds the cell count by
the CEK method (breast cancer: R
2¼0.004919; lung cancer:
R
2¼0.006952). To determine whether the observed yield differences
between the CEK and CPK methods are due to differences in the
method of cell counting (manual vs semi-automatic), we compared
CTC counts obtained using the automated CEK method with that of
a manual cell count of the same sample. The manual CEK count was
performed by removing the enumerated samples from the ‘MagNest’
cartridges, processing them as cytospin preparations and counting
them manually. In patients (n¼75 patients; 100 samples) with
breast cancer (Supplementary Figure S1E), the median cell count
using the semi-automated CEK method was 4 per 7.5ml of blood
(range 0–57) compared with 5 per 7.5ml of blood (range 0–61)
when the CEK processed specimens were counted manually
(P¼NS). Similarly, in NSCLC patients (n¼71 patients; 100
samples), the median cell count using the semi-automated CEK
method was four per 7.5ml of blood (range 0–53) compared with
five per 7.5ml of blood (range 5–67) when the CEK processed
specimens were counted manually (P¼not significant; Supplemen-
tary Figure S1F). We further compared these findings on a per
patient basis (Supplementary Figures S1C and S1D) and observed a
strong correlation between the cell counts obtained using the semi-
automated CEK method with the manual CEK method (breast
cancer specimens: R
2¼0.9930; lung cancer specimens: R
2¼0.7200).
Together, our findings suggest that the CPK method isolates a
greater number of cells than the CEK method and that these
findings are not due to differences in the method of cell counting.
The CPK method isolates a highly enriched population
of CTCs
One explanation for the improved yields observed with the CPK
method is that the isolated cells are not all CTCs but instead a
mixture of CTCs and contaminating leukocytes. This determina-
tion is critical if the isolated cells are to be used for any subsequent
analyses. To determine the composition of the cells isolated using
the CPK method, we performed IF using anti-CD45 and anti-
cytokeratin (AE1/AE3) antibodies in 30 NSCLC and 30 breast
cancer patients. Three distinct cell populations were observed: (1)
CD45 positive, cytokeratin negative, (2) CD45 negative, cytokeratin
positive, and (3) cells that were negative for both CD45 and
cytokeratin but stained with the nuclear stain DAPI (Figure 2C).
Approximately 60% of cells isolated by CPK (range: 21–95%) were
identified as tumour cells by cytokeratin staining, whereas 6%
(range: 1–22%) were identified as white blood cells (WBCs) by
CD45 staining (Figure 2A and data not shown). These percentages
correspond to a median absolute number of cytokeratin positive
cells of 280 per sample (range 20–20000) and a median of 34
(range 20–476) CD45-positive cells per sample. The remaining
32% (range: 5–68%) of cells stained with DAPI only and could
not be classified as either tumour cells or leukocytes. As a
complementary approach, we used fluorescence-activated cell
sorting on 11 patients (eight NSCLC and three breast cancer) to
compare the populations of CTCs with WBCs (Figure 2B). The
results were similar for cytokeratin (mean positive: 61%; range
35–77%), except the frequency of WBCs was estimated to be even
lower (mean positive: 1%; range 0–7%) than by IF (compare
Figure 2A and B).
As an additional method to evaluate the nature of the cells
isolated using the CPK method, we performed FISH using probes
for HER2, EGFR, and MET. Given that a mean of 32% of cells had
denuded membranes (DAPI-only cells; Figure 2A) and thus could
not be definitely stained for cytokeratin, the identification of
aneuploidy and/or gene amplification in a high fraction of the cells
would strongly suggest that some or all of these cells were CTCs
and not WBCs (Figures 3A and B). Among the CTCs from patients
with breast cancers clinically defined as HER2 positive from
analyses of their primary tumours (FISHþ and/or IHC 3þ by
local testing, n¼24), 72% of all captured cells had a HER2 gene
copy number X4. This threshold has been used as an indicator of
HER2 amplification in previous studies (Meng et al, 2004). Only
3% of the cells had two copies of HER2. In an additional six
patients with clinically defined HER2-negative breast cancers, only
5% of captured cells had X4 copies of HER2 (Figure 3D). In
contrast, the majority (95%) of cells in those patients had a HER2
gene copy number of 2 (Figure 3D). Similarly, among samples
from NSCLC patients (n¼30), 53% had X4 copies of EGFR and
13% had X4 copies CEP 7 (Figure 3C). Only a minority of cells
(5%) had two copies of EGFR and CEP 7.
As an additional control, we analysed 40 samples from healthy
volunteers with no history of malignant disease. No tumour cells
were found with either the CEK semi-automated enumeration or
with the CPK manual count (Supplementary Figure S2A). In
samples processed using the CPK method, the median total
number of cells was five per 7.5ml of blood (range: 0–50). These
cells were positive for CD45 and negative for cytokeratin using IF,
with only two gene copies of CEP7/EGFR or HER2 as detected by
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Figure 1 CPK method improves cell yields over CEK method. The blood samples from patients with (A) breast cancer (n¼75) or (B) NSCLC (n¼71)
processed in parallel by the CEK method with semi-automated quantification (open columns) or the CPK method with manual quantification (closed
columns).
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sFISH analysis, consistent with normal WBC. Collectively, these
data indicate that that majority of cells captured by the CPK
system are in fact CTCs with only a minority of cells being WBCs.
All of the samples described were prepared using the low-speed
cytospin method using a single cytology funnel with thin filter
(see Materials and Methods section). We also evaluated other
techniques for preparing slides, including high-speed cytospin,
different funnel types, a thin prep or cell block, and applying the
samples to slides directly as a smear. In a comparative analysis,
the low-speed cytospin method produced the highest yield, with
the least contamination, least cell damage, and the least slide-to-
slide variation in comparison to other various methods (data not
shown).
The CPK method has low intrapatient variability and
samples are stable for at least 72h
We next examined whether the number of cells isolated from
patients with cancer using the CPK method was reproducible and
stable over time. We first obtained three samples from each of
seven patients with NSCLC at the same time point and processed
them in parallel. The number of cells isolated was similar
(Supplementary Figure S3C) with a low coefficient of variability
(CV: 9.7%). We also evaluated the impact of time on the ability to
isolate CTCs using the CPK method. As many clinical trials involve
multiple centres, it is important to determine the stability of
unprocessed samples to determine whether the yield of CTCs
declines over time. For these studies, we collected three CellSave
(LLC a Johnson&Johnson company, Raritan, NJ, USA) or EDTA
tubes from seven NSCLC patients and incubated the samples at room
temperature for 24–72h before processing by the CPK method. We
specifically evaluated the collection of blood into both CellSave and
EDTA tubes to determine the impact of the fixative (present in the
CellSave tubes; absent in the EDTA tubes) on the impact of cell
recovery over time. We isolated similar numbers of cells using both
the CellSave (Supplementary Figure S3A) and EDTA tubes
(Supplementary Figure S3B). There was no significant decline
(coefficient of variation (CV) 9.1% and CV 6.5%) in the number of
cells isolated with either method over the 72-h period and no decline
in the number of cells isolated from CellSave tubes incubated at
room temperature for up to 144h (Supplementary Figure S3A and
data not shown). However, there was significant decline in the
number of cells isolated from EDTA tubes incubated at room
temperature for X96h before processing by the CPK method.
Treatment affects yield of cell recovery
Previous studies have found that when tumour cell lines are spiked
into blood and isolated using the CEK method, the rate of cell
recovery is high (85–95%; Riethdorf et al, 2007). However, the
actual CTC yields from cancer patients using the CEK method are
limited (Sleijfer et al, 2007). We hypothesised that one explanation
for the low yields seen in clinical practice is that CTCs are more
‘fragile’ than cancer cell lines either due to apoptosis or damage
acquired during transit through the bloodstream and, therefore,
are not captured as efficiently with the anti-epithelial cell adhesion
molecule antibodies and/or are lost in the post-capture washing
and labelling steps. To investigate this possibility, we examined
breast (SKBR3; HER2 amplified) and lung cancer (HCC827; EGFR
del E746_750) cell lines either unprocessed or spiked into normal
blood, then processed with the CPK or CEK methods. Cells were
pretreated with the EGFR/HER2 inhibitor lapatinib (SKBR3) or the
EGFR inhibitor gefitinib (HCC827) to induce apoptosis, or were
untreated. The cells were then stained with Ki67 or Apoptosis
Detection Using Terminal Transferase and Biotin-16-dUTP (TUNEL)
to evaluate proliferating and apoptotic cells, respectively. As
expected, unprocessed cells demonstrated increased rates of
apoptosis and decreased proliferation when treated with inhibitor
(Figure 4C). Interestingly, no apoptotic cells were noted in the
samples processed with the CEK method in either untreated or
treated samples, although the treated cells that were captured by
that method did have decreased levels of Ki67 staining, consistent
with the effect of the inhibitor (Figure 4A). In samples processed
with the CPK method, a small percentage of TUNEL-positive cells
were recovered in the untreated samples, which increased with
inhibitor treatment, although not to the level of unprocessed
samples (Figure 4B).
We also evaluated the frequency of Ki67- and TUNEL-staining
cells isolated from seven NSCLC patients using the CPK method.
The frequency of TUNEL-staining cells was low (mean 1.9%; range
0–6.4%) similar to what was observed in the SKBR3 and NSCLC
cell lines (Figure 4D). The frequency of Ki67-staining cells was
also lower (mean 0.7%; range 0.3–1.2%) in the CTCs from cancer
patients compared with the levels seen with cell lines (Figure 4D).
When parallel samples were processed using the CEK method, no
TUNEL-positive cells were detected, but the fraction of Ki67-
positive cells was numerically higher than in the CPK processed
samples (Figure 4E). This observation is consistent with the
hypothesis that potentially more ‘fragile’ apoptotic and non-
proliferating cells are disproportionably lost by the more
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Figure 2 The CPK method isolates a highly enriched population of
CTCs. Percentage of total cells captured by the CPK method from patients
with NSCLC, staining for cytokeratin (AE1/AE3), CD45, or DAPI nuclear
stain alone by (A) immunofluorescence or (B) FACS. Similar results were
seen with samples from patients with breast cancer. (C) Representative
immunofluorescence image of CPK-captured cells from patient with
NSCLC, labelled with cytokeratin (green), DAPI (blue), and CD45 (red).
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sprocessing intensive CEK method. However, because of the small
number of cells recovered, it was not possible to make a definitive
comparison. Together with the data obtained from the cell lines,
these findings suggest that CTCs undergoing apoptosis in the
blood stream, either spontaneously or as result of treatment effect,
may be too fragile to survive the capture step and/or are being
eliminated during subsequent specimen processing. This effect
seems to be more pronounced with the CEK than CPK method and
may help explain the increased CTC yields seen with the latter
technique. These observations may also help to explain why
alternative CTC-capture techniques, such as the microfluidic chip
or microfiltration systems that minimise the number of labelling
and wash steps are associated with an increase in CTC yield over
the CEK method.
Characterisation of HER2 amplification of CTCs by
FISH analysis
Several small studies have reported varying degrees of discordance
between the HER2 status of a patient’s breast cancer CTCs and that
of their primary tumour (Meng et al, 2004; Wulfing et al, 2006;
Pestrin et al, 2009). No data exists examining the relationship
between the CTCs’ HER2 status and that of metastatic tissue. We
hypothesised that the ability of the CPK technology to provide
relatively high numbers of CTCs and allow robust FISH analysis
would facilitate the determination of the relationship between the
HER2 status of a patients primary breast cancer, metastatic lesions,
and CTCs. To test this hypothesis, we assessed the presence of
HER2 amplification by FISH, normalised for CEP 17, on CTCs
from 75 women with breast cancer for whom the HER2 status of
the primary cancer and a metastatic biopsy sample was available
(patient characteristics available in Supplementary Table S1).
For patients with HER2 gene amplification of their primary
breast cancer, the degree of concordance with the HER2 status of
their CTCs was high, with only 1 of 45 (2%) patients demonstrating
loss of HER2 amplification in the corresponding CTCs (Table 1). In
that one patient with discordance, the metastatic biopsy was HER2
amplified, reflecting the primary cancer. In contrast, for those
patients in whom the primary breast cancer was HER2 negative,
significant discordance between the primary, metastatic biopsy,
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Figure 3 FISH analysis confirms that samples processed by the CPK method have a low percentage of contaminating normal cells. Representative FISH
images of cells processed by CPK method, (A) lymphocyte with two copies of CEP7 (green), EGFR (red), and MET (blue), (B) CTC with amplified EGFR
and MET. (C) Percentage of total cells captured by the CPK method from patients with NSCLC with X4 copies of EGFR, CEP7, and MET per nucleus.
(D) Percentage of total cells captured by the CPK method from patients with clinically defined HER2-positive (patient number 1–24) or HER2-negative
(patient number 25–30) breast cancer, with the indicated copies of HER2 per nucleus.
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sand CTC was observed. A total of 10 (33%) of these 30 patients
with HER2-negative primary cancers had HER2-positive CTCs
by FISH analysis. The median HER2/CEP17 ratio of the CTCs in
these patients was 7.1. Interestingly, in 9 of the 10 patients with
discordance, the metastatic biopsy specimen was HER2 negative.
Evaluation of biologic properties of CTCs isolated using
the CPK method
Expression of receptor tyrosine kinases The CPK method is able
to isolate a highly enriched population of CTCs and greater
numbers of CTCs than the CEK method. These findings provide
the opportunity to initiate the molecular characterisation of CTCs.
In addition to FISH (Figure 3), we evaluated the membrane
expression of total and phosphorylated HER2 and EGFR using IF
on the breast and lung cancer cell lines spiked into blood and
recovered with the CPK (Supplementary Figure S4A). The IF
analysis was superior to chromogenic immunohistochemical
staining, as the immunohistochemical substrate tended to bind
non-specifically to ferroparticles, and resulted in high background
staining (data not shown). We evaluated the expression of EGFR
and pEGFR from CTCs in seven NSCLC patients (Supplementary
Figure S4C). We were able to detect staining in all samples
although the percent of cells staining for either EGFR or pEGFR
was lower than in the HCC827 cells that had been spiked into
blood and processed using the CPK method. We also used IF to
evaluate membrane staining of EGFR, pEGFR, HER2 and pHER in
CTCs from 20 patients with clinically HER2-positive breast cancer
(Supplementary Figure S5B). Similar to the CTCs isolated from
NSCLC patients, we were able to detect EGFR, pEGFR, HER2, and
pHER using IF in the CTCs and the frequency of staining was less
than in the SKBR3 tumour cell line (Supplementary Figure S5B).
In vitro propagation The standard CellSave tubes contain a
fixative that prevents the isolation of viable tumour cells. Having
observed that CTCs can be efficiently isolated from the
blood drawn in EDTA tubes that do not contain a fixative
(Supplementary Figure S3B), we explored whether we could isolate
SKBR3 and HCC827 cells using EDTA tubes and grow them
in vitro. We spiked a range (5–1000) of SKBR3 or HCC827 cells
into the normal blood drawn into EDTA tubes and processed them
using the CPK method. We were able to isolate viable SKBR3 and
HCC827 cells (Supplementary Figure S5) and propagate them
in vitro. However, this required a minimum input of 50 cells to be
processed (Supplementary Figure S5). Optimal growth occurred
in the presence of enriched medium and cell adhesion matrix
(data not shown).
DISCUSSION
One of the most important issues limiting the use of CTCs as an
alternative to invasive biopsies has been their relatively low yield.
Using the CellSearch System (Veridex), the most widely available
technology, the median yield is reported to be in the range of 1 cell
per ml of blood screened (Cristofanilli et al, 2004). Our results with
patients with breast and lung cancer using the CellSearch CEK
platform are consistent with that finding. However, two seemingly
paradoxical observations prompted us to explore this technology
further. The first is that several studies using the CellSearch
platform have demonstrated that the instrument was highly
efficient at capturing immortalised breast cancer cell lines spiked
into the human blood, with yields of X85% of the input cells
(Allard et al, 2004). We have replicated those studies with similar
results; a capture rate of 92% (data not shown). The second
observation was the finding that the new CTC–chip microfluidic
technology reported mean CTC counts from patients with breast
cancer of 79 cells per ml of blood (Nagrath et al, 2007). If the
CellSearch technology is already highly efficient at capturing CTCs
in model systems using cancer cell lines, how can another
technology report 10–100-fold higher yields of CTCs from patient
samples? We postulated that human CTCs, particularly those that
have been subject to anti-cancer treatment, may be significantly
more ‘fragile’ than the cancer cell lines used in the initial
evaluation of the CellSearch platform. Owing to this fragility, the
multiple processing steps involved in the CEK system, including
additional washes and labelling steps, could cause degradation and
loss of captured CTCs.
We hypothesised that the CPK system, which involves
significantly fewer processing steps, may provide improved yields
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Patient
Method Number of
evaluable
samples
KI67+
cells/total
cells (mean, %)
KI67+
cells/total
cells (range, %)
KI67+
cells/sample
CEK breast 28 21.1 10 – 44 1–6
CPK breast  2 – 480
CEK lung 32
CPK lung 1–113
75 7.1 1.1 – 13.2
2–8 10 – 64 21
70 4.4 1.6 – 16
Figure 4 Apoptotic CTCs are less effectively captured by CEK or CPK
methods. SKBR3 (HER2
þ breast cancer) or HCC827 (EGFR mutant
NSCLC) cells treated with vehicle or tyrosine kinase inhibitor (SKBR3: 1mM
lapatinib and HCC827; 1mM gefitinib) for 24h and processed with (A)
CEK method. (B) CPK method or (C) smeared directly on slide without
processing. Plots depict percentage of cells (±1 s.d.) staining for Ki67
(open bars, proliferation marker) or TUNEL (closed bars, apoptosis
marker) by immunohistochemistry. (D) Percentage of CPK-processed
CTCs from patients with NSCLC staining positive for KI67 and TUNEL. (E)
Comparison of KI67 expression in CTCs recovered by CEK or CPK
methods.
Table 1 Relationship between HER2 amplification of primary cancer and
that of CTC
Primary
tumor
Total No.
of
patients
Patients
with
HER2 CTCs
Patients
with
HER2+CTCs
a Discordance
HER2+ 45 1 44 2%
HER2  30 20 10 33%
Abbreviations: CTC¼circulating cancer cells; HER2¼human epidermal growth
factor receptor 2.
aHER2 positive defined as ratio of HER2/CEP17 X2.0 by FISH.
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sof CTCs from patient samples. Indeed, we observed that the CPK
consistently provided a significantly greater yield of CTCs than
that obtained with the CEK platform. The median difference was
29-fold in breast cancer samples and 36-fold in lung cancer
samples (Figure 1). In addition, virtually all of the breast and lung
patients had detectable CTCs using the CPK method, whereas our
results with the CEK system demonstrate only 72% of patients had
detectable CTCs, consistent with the published results (Hayes et al,
2006). The improvement in yield observed with the CPK was not
simply due to the differences between the CEK’s semi-automated
counting system and the CPK’s manual counts (Supplementary
Figures S1E and F). When the CTCs from both methods were
counted manually, the differences persisted. Instead, our observa-
tion that when cell lines were pretreated with apoptosis-inducing
agents (Figure 4), the yield of CTCs dropped dramatically, suggests
that CTC fragility, coupled with the more intensive processing
inherent in the CEK method, likely accounts for the observed
differences between the CEK and CPK methods.
Importantly, we also found that the purity of the CTCs obtained
from the CPK method was quite high, typically in the 60–70% range.
This was somewhat unexpected as discussions of the CellSearch
system in the literature cite purities in the 0.01–0.1% range, due to
contaminating leukocytes. In our studies with the CPK system, the
number of contaminating leukocytes, using either patient samples or
blood from normal volunteers, and assessed using multiple
independent methods, (IF, fluorescence-activated cell sorting),
ranged from 20 to 476, and was always less than 25% of total cells.
The one study we identified describing the number of contaminating
leukocytes observed with the CPK method reported a range of 60–
929 CD45-positive cells per sample (Sieuwerts et al, 2009). This study
did not report the percentage of CTCs vs leukocytes in their paper, so
their results cannot be compared with our data in that regard.
As has previously been demonstrated with the CEK system, we
observed that the CPK method has high intrapatient reproduci-
bility and that blood samples remain stable at room temperature
for up to 72h before sample processing (Allard et al, 2004). As
many clinical trials involve multiple centres, this sample stability
provides the opportunity to collect specimens from multiple sites
and analyse them in one central location. This is an advantage over
the recently developed microfluidic-based CTC-chip method. That
technology has a very low throughput and a requirement for
samples to be run within 2h of being drawn (Nagrath et al, 2007).
These limitations make it currently incompatible for use in
multicentre clinical trials.
The CPK method clearly does not replace the CEK technique’s
well-validated usefulness as a prognostic tool for clinical samples.
Instead, we feel that the CPK technique’s relatively high yield,
purity, and sample stability make it well suited for use in obtaining
CTCs for molecular characterisation, facilitating clinical pheno-
typing and investigational studies. As an example of the former, we
have used the technique to assess the HER2 gene amplification
status of CTCs by FISH and compared it with both the patient’s
primary breast cancer and tissue from matched distant metastatic
sites. In patients with clinically HER2-positive primary and
metastatic cancers, virtually all (98%) also had HER2-amplified
CTCs. In contrast, in patients with clinically HER2-negative
primary cancers, we observed a significant number (33%) of
discordant cases in which a patient’s CTCs had clear amplification
of the HER2 locus, despite an absence of HER2 amplification in
the primary cancer. This result is consistent with the data from
several other small studies demonstrating discordant HER2
expression in CTCs and together provide the rationale for a
clinical trial of a HER2-directed therapy in such patients to
definitively test the clinical relevance of this observation (Meng
et al, 2004; Wulfing et al, 2006; Pestrin et al, 2009). To the best of
our knowledge, our study is the first to also examine the
relationship between HER2 amplification in CTCs and that of
metastatic biopsy tissue. In six out of seven patients with HER2-
negative primary cancers and HER2-amplified CTCs, the meta-
static biopsy tissue was HER2 negative, matching the primary
cancer rather than the CTCs. This observation suggests that either
CTCs represent a separate population of cells distinct from that
which makes up the bulk of the metastatic disease, or that the
cancer developed HER2 amplification in the interval between
the patients’ metastatic biopsy and the CTC collection. If the latter
explanation were correct, one might expect to see a correlation
between the time interval from biopsy to CTC collection and the
likelihood that the CTC would gain HER2 amplification. Although
we did not observe such a trend (data not shown), our sample size
is too small to make any conclusions about the mechanism of this
discordance.
In summary, we have demonstrated that using the CellSearch
CPK assay, an instrument that is currently available in hundreds
of clinical and research laboratories, CTCs can be isolated in
sufficient numbers and of sufficient purity to allow for their
molecular characterisation. This technology potentially has a large
number of applications in investigating the biology of metastatic
cancer and in drug development in which it can be used to identify
predictive biomarkers, mechanisms of resistance, and facilitate
pharmacodynamic studies.
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